Interestingly, IGF2 can be used as a prognostic marker since its methylation status can be screened by epigenetic blood testing in order to identify early in life LS carriers that are highly susceptible to developing CRC [53]. The gene discussed is IGF2; the disease is colorectal carcinoma.